Zobrazeno 1 - 10 of 51 pro vyhledávání: '"Ronald W. Barrett"'
1
Akademický článek
A mechanistically novel peptide agonist of the IL-7 receptor that addresses limitations of IL-7 cytokine therapy.
Autor: William J Dower, Angie Inkyung Park, Alice V Bakker, Steven E Cwirla, Praechompoo Pongtornpipat, Blake M Williams, Prarthana Joshi, Bryan A Baxter, Michael C Needels, Ronald W Barrett
Publikováno v: PLoS ONE, Vol 18, Iss 10, p e0286834 (2023)
Interleukin (IL)-7 is broadly active on T-cell populations, and modified versions have been clinically evaluated for a variety of therapeutic applications, including cancer, lymphopenia, and infectious diseases; and found to be relatively well-tolera
Externí odkaz: https://doaj.org/article/3bd59ccdb97e4f0fb8a0e9145823542e
Zobrazit plný text záznamu
2
A mechanistically novel peptide agonist of the IL-7 receptor that addresses limitations of IL-7 cytokine therapy
Autor: William J. Dower, Angie Inkyung Park, Alice V. Bakker, Steven E. Cwirla, Praechompoo Pongtornpipat, Blake M. Williams, Prarthana Joshi, Bryan A. Baxter, Michael C. Needels, Ronald W. Barrett
Interleukin (IL)-7 is broadly active on T-cell populations, and modified versions have been clinically evaluated for a variety of therapeutic applications, including cancer, lymphopenia and infectious diseases; and found to be relatively well-tolerat
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7ff65917a24a1a813fbc673b68412542
https://doi.org/10.1101/2023.05.24.542196
Zobrazit plný text záznamu
3
709 Peptidyl IL-2/15Rβγc-restricted agonists, highly-attenuated and linked to anti-PD-1 antibodies to achieve selectivity and amplified potency in stimulating PD-1high lymphocytes
Autor: William J. Dower, Steven E. Cwirla, Bakker Alice, Prarthana Joshi, Ronald W. Barrett, Michael C. Needels, Praechompoo Pongtornpipat, Blake Williams
Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundRecent reports demonstrate that directing a “non-alpha” IL-2 mutant to a PD-1high CD8+ stem-like population induces proliferation, and differentiation into a highly functional cytotoxic phenotype. We previously reported small synthetic
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff6bf2011e2147318bab92b56b923f54
https://doaj.org/article/1b97f15b8df443b49bcae65a6577cdad
Zobrazit plný text záznamu
4
Abstract 2066: In vitro and in vivo properties of MDK703: An Fc-peptide fusion IL-7Rαγc agonist unrelated in structure to IL-7
Autor: Angie I. Park, Steven E. Cwirla, Alice V. Bakker, Blake M. Williams, Prarthana Joshi, Praechompoo Pongtornpipat, Sandra M. Wang, Bryan Baxter, Michael C. Needels, Ronald W. Barrett, William J. Dower
Publikováno v: Cancer Research. 82:2066-2066
Background: IL-7 receptor activation is essential for the proper development and homeostasis of T-cell subpopulations, and maintenance of the TCR clonal repertoire. Emerging evidence indicates potential clinical utility of IL-7 for immunotherapy of l
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0ad7d9c234b8b182dd62d13430c7bf46
https://doi.org/10.1158/1538-7445.am2022-2066
Zobrazit plný text záznamu
5
567 MDK1319/MDK-701: A potent fully efficacious peptidyl agonist of IL-7Rαγc, designed with no reference to cytokine or receptor structure and unrelated to IL-7, fused to an Fc-domain for PK enhancement
Autor: Ronald W. Barrett, Bakker Alice, Praechompoo Pongtornpipat, Blake Williams, Michael C. Needels, Steven E. Cwirla, Prarthana Joshi, William J. Dower, Sandra Wang
Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background IL-7 receptor activation is essential for the proper development and homeostasis of T-cell subpopulations, and maintenance of the TCR clonal repertoire. Emerging evidence indicates potential clinical utility of IL-7 for immunotherapy of ly
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1870a9c8a04ce0816bd5523b07b5d828
https://doaj.org/article/39219be9b5974bbeaf2f38cc3bb3e06a
Zobrazit plný text záznamu
6
566 MDK-202: An empirically-designed peptidyl agonist of the IL-2/15βγc receptor, devoid of Rα interaction, unrelated to IL-2 or IL-15, and fused to an Fc-domain for PK enhancement
Autor: Sandra Wang, Bakker Alice, Steven E. Cwirla, Praechompoo Pongtornpipat, Ronald W. Barrett, Blake Williams, Michael C. Needels, William J. Dower, Prarthana Joshi
Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Efforts to modify IL-2 for immuno-oncology applications focus on modifying the receptor selectivity of IL-2 to bias effects on immune cells; in particular, to reduce Rα interaction via mutation, chemical modification, complexation with an
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7aab93904f7ed17a8327f5fefe28b023
https://doaj.org/article/accd91a16d9c485a85884167210aa877
Zobrazit plný text záznamu
7
691 MDK-271: A dual function molecule consisting of empirically-designed peptidyl agonists of IL-2/15Rβγc and IL-7Rαγc, unrelated to IL-2, IL-15, or IL-7, incorporated into a bispecific Fc fusion protein
Autor: Ronald W. Barrett, Steven E. Cwirla, Michael C. Needels, Prarthana Joshi, William J. Dower, Sandra Wang, Praechompoo Pongtornpipat, Bakker Alice, Blake Williams
Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Activation of IL-2/15Rβγc or IL-7R on immune cells using modified versions of IL-2 or IL-7 is under investigation as monotherapy, or in combination with checkpoint inhibitors, engineered T or NK cells, or neo-antigen vaccines. We previou
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8118cd5ef554d635457d184d4279c52b
https://doi.org/10.1136/jitc-2020-sitc2020.0691
Zobrazit plný text záznamu
8
Dose Response of Gabapentin Enacarbil versus Placebo in Subjects with Moderate-to-Severe Primary Restless Legs Syndrome
Autor: Ronald W Barrett, Susan VanMeter, Samantha Warren, Sarah Kavanagh
Publikováno v: CNS Drugs. 26:773-780
Background: The efficacy and tolerability of gabapentin enacarbil (Horizant®; GlaxoSmithKline, Brentford, UK) has been demonstrated in several restless legs syndrome (RLS) phase II and phase III clinical studies at various doses from 600 mg to 2400
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b382e2183d1c8facacbce154541e85b
https://doi.org/10.2165/11634870-000000000-00000
Zobrazit plný text záznamu
9
Long-term Maintenance Treatment of Restless Legs Syndrome With Gabapentin Enacarbil: A Randomized Controlled Study
Autor: Pierre V. Trân, Ronald W. Barrett, Richard K. Bogan, Michel A. Cramer Bornemann, Clete A. Kushida
Publikováno v: Mayo Clinic Proceedings. 85:512-521
OBJECTIVE To assess maintenance of efficacy and tolerability of gabapentin enacarbil in patients with moderate to severe primary restless legs syndrome (RLS). PATIENTS AND METHODS This study (conducted April 18, 2006, to November 14, 2007) comprised
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::741fecd5546b8bcea366e90ab81392fe
https://doi.org/10.4065/mcp.2009.0700
Zobrazit plný text záznamu
10
A Randomized, Double-Blind, Placebo-Controlled, Crossover Study of Xp13512/Gsk1838262 in the Treatment of Patients With Primary Restless Legs Syndrome
Autor: Ronald W. Barrett, Philip M. Becker, Daniel M. Canafax, A. Thomas Perkins, Arthur S. Walters, Clete A. Kushida, Thomas Roth, Stephen G. Thein
Publikováno v: Sleep. 32:159-168
TWO TO 3 PERCENT OF THE US POPULATION EXPERIENCE CLINICALLY RELEVANT SYMPTOMS OF PRIMARY RESTLESS LEGS SYNDROME (RLS) SEVERE enough to warrant treatment.1–3 Patients with RLS report difficulty falling asleep and exhibit abnormal sleep architecture,
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d18655b0e810b5537aa922d11070aaaf
https://doi.org/10.1093/sleep/32.2.159
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje